Notice of Change to Key Dates for PAR-18-628 "NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)"
Notice Number:
NOT-NS-20-090

Key Dates

Release Date:

August 11, 2020

Related Announcements

PAR-18-628 - NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The purpose of this notice is to inform interested applicants of a change to the Key Dates for PAR-18-628 "NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)(changes shown below in bold italics). This Funding Opportunity Announcement has

been extended by one additional council round. The dates have been modified to add the following New Application Due Date: April 5, 2021.

Currently Reads:

Part 1. Overview Information

Key Dates

Application Due Date(s)

Standard dates apply , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Scientific Merit Review Standard dates apply
Advisory Council Review Standard dates apply
Earliest Start Date Standard dates apply
Expiration Date January 6, 2021

Modified to Read:

Part 1. Overview Information

Key Dates

Application Due Date(s)

Standard dates apply , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Scientific Merit Review Standard dates apply
Advisory Council Review Standard dates apply
Earliest Start Date Standard dates apply
Expiration Date April 6, 2021

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Codrin Lungu, MD
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-9135
Email: lunguci@ninds.nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices